| NKCx Histopathological outcome* within 12 months after cervix cytology in 2024 |
| 551 Örebro |
| Benign | LSIL | HSIL | AIS | Cancer | Other | PAD missing | Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cytologi | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benign sample | 69 | 10.3% | 3 | 0.4% | 11 | 1.6% | . | . | . | . | 5 | 0.7% | 583 | 86.9% | 671 | 100.0% |
| ASCUS | 204 | 56.0% | 79 | 21.7% | 39 | 10.7% | 1 | 0.3% | 2 | 0.5% | 9 | 2.5% | 30 | 8.2% | 364 | 100.0% |
| LSIL | 108 | 42.5% | 68 | 26.8% | 48 | 18.9% | . | . | . | . | 5 | 2.0% | 25 | 9.8% | 254 | 100.0% |
| Atypical glandular cells/AGC | . | . | . | . | 2 | 50.0% | 2 | 50.0% | . | . | . | . | . | . | 4 | 100.0% |
| Unclear atypia | . | . | . | . | 1 | 50.0% | 1 | 50.0% | . | . | . | . | . | . | 2 | 100.0% |
| HSIL | 8 | 14.5% | 4 | 7.3% | 37 | 67.3% | 1 | 1.8% | 1 | 1.8% | 3 | 5.5% | 1 | 1.8% | 55 | 100.0% |
| Totalt | 389 | 28.8% | 154 | 11.4% | 138 | 10.2% | 5 | 0.4% | 3 | 0.2% | 22 | 1.6% | 639 | 47.3% | 1350 | 100.0% |
| NOTE: Histopathological outcome from T83x taken into account. |
| This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad. |
| * Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead. |
| The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'. |
| Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories. |
| Snomed codes in the category Cancer: |
|---|
| M80703, M81403 |